Eli Lilly and Company (NYSE:LLY) is one of the best performing pharma stocks in 2025. Eli Lilly and Company (NYSE:LLY) ...

After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition ...

A report in the Wall Street Journal, citing people familiar with the matter, suggested an announcement of a transaction could ...

The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.

It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...

Eli Lilly and Company and Ventyx Biosciences entered into a definitive agreement under which Eli Lilly will acquire Ventyx in ...

Detailed price information for Ventyx Biosciences Inc (VTYX-Q) from The Globe and Mail including charting and trades.

Fintel reports that on January 8, 2026, Wells Fargo downgraded their outlook for Ventyx Biosciences (NasdaqGS:VTYX) from ...

Biopharma stocks may rally in 2026 as M&A heats up and drug pricing uncertainty fades—see why UBS expects big pharma to buy ...

Eli Lilly (LLY) downgraded to Sell as obesity-drug competition and pricing pressure rise; stretched valuation boosts downside ...

Eli Lilly has announced that it has entered into a definitive agreement to acquire Ventyx Biosciences, a biopharmaceutical ...

Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has ...